MedTrace Logo

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

NCT04360044 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-02-28

No results posted yet for this study

Summary

This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.

Conditions

Interventions

DRUG

THC ~5%

4 puffs of vaporized flower containing THC \~5%

DRUG

CBD ~12%

4 puffs of vaporized flower containing CBD \~12%

DRUG

THC ~5% and CBD ~12%

4 puffs of vaporized flower containing THC \~5% and CBD \~12%

DRUG

Sham Cannabis

4 puffs of vaporized flower from which the THC and CBD have been extracted

Sponsors & Collaborators

Principal Investigators

  • Nathaniel M Schuster, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2023-02-23
Completion
2023-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04360044 on ClinicalTrials.gov